To study the influence of glucocorticoid replacement therapy on bone mineral density.




University hospital in the Netherlands.


91 patients with Addison disease who had been receiving glucocorticoid replacement therapy for a mean of 10.6 years (range, 0.5 to 36.5 years).


Bone mineral density of the lumbar spine and both femoral necks using a dual-energy x-ray absorptiometer and basal serum concentrations of adrenocorticotropin, gonadal hormones, and adrenal androgens.


Decreased bone mineral density (< 2 standard deviations [SD] of the mean value of an age-matched reference population) was found in 10 of 31 men (32%; 95% CI, 17% to 51%) and in 4 of 60 women (7%; CI, 2% to 16%). No statistically significant differences were found between men and women with regard to age, duration of glucocorticoid substitution, or glucocorticoid dose, either in absolute quantities or when expressed per kilogram of body weight. However, in men with decreased bone mineral density, the daily hydrocortisone dose per kilogram of body weight (0.43 ±0.08 mg/kg; mean ±SD) was significantly (P = 0.032) higher than in men with normal bone mineral density (0.35 ±0.10 mg/kg). After correction for possible confounding variables, a significant linear correlation was found between hydrocortisone dose per kilogram of body weight and bone mineral density of the lumbar spine in the men (regression coefficient, −0.86;CI, −1.60 to −0.13; P = 0.029) but not in the women.


Long-term treatment with standard replacement doses of glucocorticoids may induce bone loss in men with Addison disease. Adjustment of glucocorticoid therapy to the lowest acceptable dose is mandatory in Addison disease, and regular measurement of bone mineral density may be helpful in identifying men at risk for the development of osteoporosis.


  • 1. Mason AS, Meade TW, Lee JA, Morris JN. Epidemiological and clinical picture of Addison's disease. Lancet. 1968; 2:744-7. Google Scholar
  • 2. Hahn TJ. Corticosteroid-induced osteopenia. Arch Intern Med. 1978; 138:882-5. Google Scholar
  • 3. Ryan PJ, Blake GM, Fogelman I. Postmenopausal screening for osteopenia. Br J Rheumatol. 1992; 31:823-8. Google Scholar
  • 4. Anderson DC. Osteoporosis in men (Editorial). BMJ. 1992; 305:489-90. Google Scholar
  • 5. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Min Res. 1992; 7:1063-9. Google Scholar
  • 6. Boyce BF, Gallacher SH, Byars J, Adamson B, Boyle IT. No osteoporosis found in premenopausal patients on long-term corticosteroid therapy for asthma (Abstract). J Bone Min Res. 1991; 6(Supp 1): S108. Google Scholar
  • 7. Devogelaer JP, Crabbe J, Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J (Clin Res Ed). 1987; 294:798-800. Google Scholar
  • 8. Schot LP, Schuurs AH. Sex steroids and osteoporosis: effects of deficiencies and substitutive treatments. J Steroid Biochem Mol Biol. 1990; 37:167-82. Google Scholar
  • 9. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med. 1990; 113:265-9. Google Scholar
  • 10. Burke CW. Primary adrenocortical failure. In: Grossman A; ed. Clinical Endocrinology. Oxford: Blackwell; 1992:393-404. Google Scholar
  • 11. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991; 71:39-45. Google Scholar
  • 12. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf). 1992; 36:229-34. Google Scholar